Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome

Heart Rhythm

Volumn 10, Issue 11, 2013, Pages 1720-1727

  Szél, Tamás ^a,b   Koncz, István ^a,b   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Cardiac arrhythmias; Electrophysiology; Pharmacology; Phosphodiesterase inhibitor; Sudden cardiac death

Indexed keywords

CARDIOVASCULAR AGENT; CILOSTAZOL; MILRINONE; NS 5806; UNCLASSIFIED DRUG; VERAPAMIL;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; BRUGADA SYNDROME; CELL ACTIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISPERSION; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAPHY; ENDOCARDIUM; EPICARDIUM; EXTRASYSTOLE; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; MEMBRANE POTENTIAL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; ST SEGMENT ELEVATION;

ACTION POTENTIAL; AP; BRS; BRUGADA SYNDROME; CAMP; CARDIAC ARRHYTHMIAS; CYCLIC ADENOSINE MONOPHOSPHATE; ECG; EDR; ELECTROCARDIOGRAM/ELECTROCARDIOGRAPHIC; ELECTROPHYSIOLOGY; ENDO; ENDOCARDIAL; EPI; EPICARDIAL; EPICARDIAL DISPERSION OF REPOLARIZATION; I(CA); I(TO); L-TYPE CALCIUM CHANNEL CURRENT; NI; NM; NOTCH INDEX; NOTCH MAGNITUDE; PDE; PHARMACOLOGY; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; RIGHT VENTRICLE/VENTRICULAR; RV; SUDDEN CARDIAC DEATH; TDR; TRANSIENT OUTWARD CURRENT; TRANSMURAL DISPERSION OF REPOLARIZATION; VENTRICULAR FIBRILLATION; VENTRICULAR TACHYCARDIA; VF; VT;

ACTION POTENTIALS; ANIMALS; BRUGADA SYNDROME; DISEASE MODELS, ANIMAL; DOGS; DRUG THERAPY, COMBINATION; HEART CONDUCTION SYSTEM; HEART RATE; MILRINONE; PHOSPHODIESTERASE 3 INHIBITORS; TETRAZOLES;

EID: 84887004876     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2013.07.047     Document Type: Article

References (36)

1. P. Brugada, and J. Brugada Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report J Am Coll Cardiol 20 1992 1391 1396
2. J.M. Di Diego, J.M. Cordeiro, and R.J. Goodrow Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males Circulation 106 2002 2004 2011
3. B.J. Boukens, M. Sylva, and Vries C. de Gier-de Reduced sodium channel function unmasks residual embryonic slow conduction in the adult right ventricular outflow tract Circ Res 113 2013 137 141
4. A.A. Wilde, P.G. Postema, and J.M. Di Diego The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization J Mol Cell Cardiol 49 2010 543 553
5. C. Antzelevitch Brugada syndrome Pacing Clin Electrophysiol 29 2006 1130 1159
6. E. Delpón, J.M. Cordeiro, and L. Núñez Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome Circ Arrhythm Electrophysiol 1 2008 209 218
7. G.X. Yan, and C. Antzelevitch Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation Circulation 100 1999 1660 1666
8. M. Endoh, T. Yanagisawa, N. Taira, and J.R. Blinks Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle Circulation 73 1986 III117 III133
9. S.T. Rapundalo, I. Grupp, G. Grupp, M.M. Abdul, R.J. Solaro, and A. Schwartz Myocardial actions of milrinone: characterization of its mechanism of action Circulation 73 1986 III134 III144
10. H. Atarashi, Y. Endoh, H. Saitoh, H. Kishida, and H. Hayakawa Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias J Cardiovasc Pharmacol 31 1998 534 539
11. 2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol Cardiovasc Drugs Ther 13 1999 105 113
12. T. Tsuchiya, K. Ashikaga, T. Honda, and M. Arita Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome J Cardiovasc Electrophysiol 13 2002 698 701
13. N. Kanlop, K. Shinlapawittayatorn, R. Sungnoon, P. Weerateerangkul, S. Chattipakorn, and N. Chattipakorn Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine Can J Physiol Pharmacol 88 2010 422 428
14. N. Kanlop, S. Chattipakorn, and N. Chattipakorn Effects of cilostazol in the heart J Cardiovasc Med (Hagerstown) 12 2011 88 95
15. Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:1335-1341
16. A. Abud, D. Bagattin, R. Goyeneche, and C. Becker Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome J Cardiovasc Electrophysiol 17 2006 210 212
17. D.L. Dawson, B.S. Cutler, M.H. Meissner, and D.E. Strandness Jr Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial Circulation 98 1998 678 686
18. C.M. Pratt Analysis of the cilostazol safety database Am J Cardiol 87 2001 28D 33D
19. S.U. Kwon, Y.J. Cho, and J.S. Koo Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis Stroke 36 2005 782 786
20. M. Marquez, G. Salica, and A.G. Hermosillo Ionic basis of pharmacological therapy in Brugada syndrome J Cardiovasc Electrophysiol 18 2007 234 240
21. J.M. Fish, D.R. Welchons, Y.S. Kim, S.H. Lee, W.K. Ho, and C. Antzelevitch Dimethyl lithospermate B, an extract of danshen, suppresses arrhythmogenesis associated with the Brugada syndrome Circulation 113 2006 1393 1400
22. J.M. Di Diego, S. Sicouri, R.C. Myles, F.L. Burton, G.L. Smith, and C. Antzelevitch Optical and electrical recordings from isolated coronary-perfused ventricular wedge preparations J Mol Cell Cardiol 54 2013 53 64
23. K. Calloe, J.M. Cordeiro, and J.M. Di Diego A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome Cardiovasc Res 81 2009 686 694
24. C. Antzelevitch, G.D. Pollevick, and J.M. Cordeiro Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death Circulation 115 2007 442 449
25. Q. Chen, G.E. Kirsch, and D. Zhang Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation Nature 392 1998 293 296
26. H. Watanabe, T.T. Koopmann, and S. Le Scouarnec Sodium channel b1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans J Clin Invest 118 2008 2260 2268
27. + current and causes inherited arrhythmias Circulation 116 2007 2260 2268
28. E. Burashnikov, R. Pfeiffer, and H. Barajas-Martinez Mutations in the cardiac L-type calcium channel associated J wave syndrome and sudden cardiac death Heart Rhythm 7 2010 1872 1882
29. D. Hu, H. Barajas-Martinez, and A. Medeiros-Domingo A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents Heart Rhythm 9 2012 760 769
30. T. Nakajima, J. Wu, and Y. Kaneko KCNE3 T4A as the genetic basis of Brugada-pattern electrocardiogram Circ J 76 2012 2763 2772
31. + channel associated with autopsy-negative sudden unexplained death Hum Mutat 33 2012 989 997
32. B. Bilginer, B. Oal, and K. Yigitkanli Treatment of cerebral vasospasm with cilostazol in subarachnoid haemorrhage model Acta Neurochir Suppl 104 2008 291 295
33. G.W. He, and C.Q. Yang Inhibition of vasoconstriction by phosphodiesterase III inhibitor milrinone in human conduit arteries used as coronary bypass grafts J Cardiovasc Pharmacol 28 1996 208 214
34. G.S. Xiao, and Y.H. Liao Effect of cilostazol on transient outward potassium current in human atrial myocytes Zhongguo Ying Yong Sheng Li Xue Za Zhi 20 2004 238 241
35. H. Suzuki, K. Torigoe, O. Numata, and S. Yazaki Infant case with a malignant form of Brugada syndrome J Cardiovasc Electrophysiol 11 2000 1277 1280
36. H. Tanaka, O. Kinoshita, and S. Uchikawa Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome Pacing Clin Electrophysiol 24 2001 1293 1294